Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Reasons why SIP is the Best Way of Investment

By Jagat Joshi
September 15, 2023

Investing your money wisely is a crucial step toward achieving your financial goals. In a world filled with various investment options, a Systematic Investment Plan (SIP) has emerged as a popular and effective method for individuals to grow their wealth steadily. Today, 47% of the investors prefer investing in SIPs. This has also made SIP the most preferred investment option.

But if you do not understand exactly what the significance for SIPs is about, then you probably need more information about it. Therefore, let’s delve into the concept of SIP and discuss how to start an investment plan in SIP.

What is SIP?

A Systematic Investment Plan or SIP is a strategy for investment that allows individuals to invest a fixed amount of money at regular intervals in specific financial instruments, such as mutual funds. Unlike lump-sum investments, SIP involves making smaller periodic investments. This approach offers several benefits and has gained popularity due to its flexibility and potential for consistent returns.

Characteristics of SIP

Some essential features of SIP that make it a popular way to invest in mutual funds are:

1. Regularity and Discipline

SIP promotes financial discipline by encouraging investors to contribute a fixed amount at predetermined monthly intervals. This instils a habit of consistent investing, helping individuals avoid impulsive decisions influenced by market volatility.

2. Flexible Investment Amount

SIP allows you to choose the amount you invest in each instalment. You can increase or decrease your investment amount if needed. This gives you the flexibility to adapt to changing financial circumstances.

3. Automatic Investment

It can be challenging to remember to invest regularly. But with SIP, you can set up an automatic process. The decided amount is automatically deducted from your bank account and invested without you needing to remember or take any action. This helps maintain consistency in your investment journey.

4. Long-Term Approach

SIP encourages a patient approach to investing. The goal is to keep your investments going, even when the market has ups and downs. By staying invested for the long term, you give your investments more time to grow despite potential temporary fluctuations.

5. Professional Fund Management

When you choose SIP and invest in mutual funds, you’re not alone in managing your money. Skilled financial experts take charge of your investments. They study the market, analyse trends, and decide where your money should be invested. This professional management can potentially lead to better results over time.

Top 7 Reasons to Invest in SIP

Some of the reasons why you should consider investing in SIPs are:

1. Accessibility and Affordability

SIPs allow investors to start with a relatively small amount, making it accessible even for those with restricted amounts of funds. This coordination of investing in SIPs enables a broader segment of the population to participate in wealth creation.

2. Risk Mitigation

SIPs help minimise the impact of market volatility by investing a fixed amount at regular intervals. The rupee cost-averaging strategy ensures that you buy more units at low prices. This reduces the overall impact of market fluctuations.

3. Disciplined Saving and Investing

SIPs instil financial discipline by automating investments. This regular contribution habit promotes a culture of saving and investing, which is essential for achieving long-term financial goals.

4. Power of Compounding

The compounding effect in SIPs can significantly amplify returns over the long run. Thus, starting early allows you to harness the full potential of compounding, turning even modest investments into substantial wealth over time.

5. Diversification Benefits

SIPs often involve investing in mutual funds, which is a pool of money from multiple investors to invest in a broad range of assets. This diversification spreads risk and enhances the potential for consistent returns.

6. Liquidity and Flexibility

SIPs offer the flexibility to withdraw or pause investments if circumstances change. This liquidity feature distinguishes SIPs from many other investment options, providing an element of financial security.

7. Goal-based Investing

SIPs can be customised to specific financial goals. These goals can be education or retirement. This goal-oriented approach allows you to align your investment strategy with your aspirations.

Steps to Start Investing in SIP

If you are wondering how to start investment in SIP, then read the steps given below:

Step 1: Set Financial Goals

Having clear objectives guides your investment decisions. Therefore, you must start by defining your financial goals and determining the purpose of your investment.

Step 2: Assess Risk Tolerance

Different mutual funds carry different levels of risk. Therefore, you must assess how comfortable you are with potential fluctuations in the value of your investments.

Step 3: Select an Investment Platform

You can invest in SIPs through various platforms. But you must select the ideal one after comparing the features and customer service different platforms offer to choose one that suits your needs.

Step 4: Complete KYC (Know Your Customer) Verification

Most investment platforms require you to complete KYC verification. This involves submitting your identity and address proof documents. Follow the platform’s instructions to complete this process.

Step 5: Bank Account Linking

You would also have to link your bank account to your investment platform. This is necessary for automatic debits of SIP amounts from your bank account.

Step 6: Choose a Suitable Mutual Fund

Mutual funds can be categorised into equity, debt, etc. Thus, you must research and select the mutual fund that aligns with your financial goals and risk tolerance.

Step 7: Register for SIP

Once your KYC is verified, you can register for SIP investments. Ensure you provide the necessary details, such as the mutual fund scheme you want to invest in, the investment amount, and the frequency.

Step 8: Set SIP Amount and Frequency

Decide the monthly investment amount and the frequency of your SIP. This amount can be as low as Rs. 500 in India, making it accessible for many investors.

Step 9: Monitor and Review

Lastly, regularly monitor the performance of your SIP investments. While SIPs are a long-term investment, reviewing your portfolio periodically (e.g., annually) is essential to make necessary adjustments.

Conclusion

Systematic Investment Plans (SIPs) have aggregated attention as the best investment method. Considering the numerous benefits SIPs provide, they offer a well-rounded investment avenue suitable for both beginners and experienced investors. Therefore, you must consider making SIPs a part of your investment portfolio. However, before investing in any investment option, conduct detailed research. This will help you make an informed decision, minimising the chances of loss.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.